A roundup of the most newsworthy healthcare press releases from PR Newswire, including Sanofi's $20B investment, Novo Nordisk's new initiatives for Wegovy® and positive topline results for an oral pill for Obstructive Sleep Apnea.

NEW YORK, June 6, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most popular releases and newsworthy trends, here's a recap of some of the past month's most read- and engaged-with stories.

The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.

1. Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies
   "As the leader in obesity care for more than a decade, it is our responsibility to continue to work with others across the US healthcare system to find innovative opportunities to meet the needs of these patients and connect them with authentic, FDA-approved Wegovy® in a convenient and affordable way," said Dave Moore, Executive Vice President, US Operations and President of Novo Nordisk Inc.
2. AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas 
   The strategic collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology, which has the potential to enable sustained and precise mRNA silencing. AbbVie will contribute its expertise in antibody engineering, antibody drug conjugates (ADCs) and tissue delivery approaches as appropriate, to augment ADARx's discovery efforts.
3. PhaseV Lands $50M Series A to Supercharge AI for Clinical Development, Backed by Top VCs and Trusted by Leading Pharma Clients
   The funding will allow PhaseV to grow its vertical AI platform to provide holistic solutions for clinical development. The platform is currently used across more than 20 therapeutic areas, including neurology, oncology, GI disorders, immunology, metabolic diseases, rare diseases, and others.
4. FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity 
   "We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD, Senior Vice President, Clinical Development, Medical & Regulatory Affairs at Novo Nordisk Inc. "We are pleased that the FDA has accepted our submission and look forward to working with regulatory authorities on what would be the first oral GLP-1 treatment for obesity."
5. Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-daily Oral Pill for Obstructive Sleep Apnea 
   "These Phase 3 topline results are highly encouraging and represent the potential for a much-needed innovation in the treatment of OSA," said Patrick Strollo, Jr., MD, study chair of the SynAIRgy clinical trial and Vice Chair of Medicine for Veteran's Affairs at the University of Pittsburgh School of Medicine. "For too long, progress in OSA has been limited, leaving many people with OSA without sustainable treatment options."
6. Function Health Acquires Ezra, Introduces $499 Full-Body MRI Scan 
   Function and Ezra together represent the exact data needed to create the new standard of care. By merging Function's extensive lab testing with Ezra's imaging, they're creating a dataset that will allow AI to become truly predictive—potentially identifying health issues before they occur.
7. Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD) 
   "These compelling results are the culmination of five years of research focused on designing and developing truly novel and optimized treatments," said Jonathan Sporn, MD, Founder and CEO of Gilgamesh Pharmaceuticals. "GM-2505's rapid and sustained antidepressant effect fits seamlessly into the existing two-hour in-clinic treatment model."
8. MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome 
   "This collaboration represents the culmination of decades of partnership and scientific innovation aimed at addressing complex monogenic neurological disorders," said Jim Wilson, MD, PhD, President and CEO of GEMMABio. "We are excited to support MavriX Bio as they advance MVX-220 into clinical evaluation – an important milestone offering renewed hope for families affected by Angelman syndrome."
9. Shaklee Continues to Expand Its Innovative Wellness Product Offering Through New Acquisition 
   The acquisition includes Modere's rights to all the trademarks, patents, and formulas for all Modere products including Liquid BioCell® Collagen and Trim – the two most popular product lines in the Modere portfolio. The acquisition also includes all the manufacturing and testing equipment in Modere's North American manufacturing facilities and all related inventory including Liquid BioCell®, Trim, Burn, Sculpt, and Curb and the rest of the Modere product portfolio.
10. FDA Approves Teal Health's Teal Wand™--The First and Only At-Home Self-Collection Device for Cervical Cancer Screening, Introducing a Comfortable Alternative to In-Person Screening 
    Kits become available in June, starting in California and expanding nationwide as soon as possible thereafter. Teal is working with major insurance providers and plans to have flexible payment options, helping to remove financial concerns and ensuring more women have access to this preferred at-home screening if they want it.
11. Pager Health and Protera Health Team Up to Expand Access to Value-Based, Virtual-First MSK Care 
    With the collaboration, Pager Health's omnichannel care navigation solution will rapidly identify members with potential MSK-related issues and connect them seamlessly to Protera Health's virtual MSK program. From there, members will be directed to in-home care, in-network physical therapy or orthopedic surgical consults as appropriate.
12. Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing 
    Of the total investment, Sanofi will substantially increase spending in the US on R&D to accelerate its science. The company also plans to expand its US manufacturing capacity, both through direct investments in Sanofi sites, as well as through partnerships with other domestic manufacturers, to help ensure the production of medicines in the US.
13. American College of Lifestyle Medicine announces integration of first set of lifestyle behavior assessment tools into Epic electronic health records 
    The new tools include ACLM's lifestyle medicine short form assessment tool, a clinical survey to capture patient lifestyle behaviors and readiness for change; ACLM's Diet Screener, which helps clinicians quickly capture a picture of a patient's diet during routine medical appointments; the Physical Activity Vital Sign (PAVS) tool for assessing physical activity in adults; as well as additional tools to capture lifestyle behaviors and opportunities for change.
14. Guardian adds over 20 new and innovative benefits to its hospital indemnity insurance policy, designed to inspire well-being® 
    Guardian's enhanced hospital indemnity insurance policy becomes one of the industry's most comprehensive offerings, going further to support workers' mental, physical, and financial well-being needs. As part of these additions, Guardian becomes the first carrier to include fertility health, family-building, and caregiving wellness solutions directly in hospital indemnity insurance.   

For more news like this, check out all of the latest health-related releases from PR Newswire.

Trending Topics

Among the health news that was distributed in May, the PR Newswire team was able spot several larger stories that highlight the trends shaping the industry.

• Mental Health: With the conclusion of Mental Health Awareness Month, we saw numerous releases highlighting initiatives to support and raise awareness for mental health. Active Minds and The ALS Association reimagined the Ice Bucket Challenge as the #SpeakYourMIND Challenge and raised over $400,000. We also saw Columbia Mental Health launch a "Myths vs. Facts" campaign which was designed to confront and correct the many misconceptions that often prevent people from getting the care they need. The American Foundation for Suicide Prevention shared details of its upcoming Out of the Darkness Overnight Walk. There was also a focus on normalizing mental health conversations and improving care access for underserved communities. And a Mars study found that the majority of pet owners (58%) prefer to spend time with their pet when feeling stressed.
• AI Integration: As more healthcare companies integrate AI into their workflow, we continue to see its impact in patient outcomes and operational efficiency. In fact, Equity Insider estimates AI could add $461 billion to global healthcare value. Among the headlines in May, Illumina's new PromoterAI algorithm intends to improve the rate of rare disease diagnosis by identifying previously overlooked variants in the noncoding genome. Somite AI announced Series A funding for its work using proprietary AI to accelerate human cell therapy development. USA News Group research suggests that the FDA has fully adopted internal AI use, a signal that we can expect to see public companies advancing their own healthcare AI platforms.

Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.

Helping Journalists Stay Up to Date on Industry News

These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.

Once they're signed up, reporters, bloggers, and freelancers have access to the following free features:

• Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.
• Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story.
• Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.
• Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.

About PR Newswire

PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

For questions, contact the team at media.relations@cision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/may-in-review-14-top-health-press-releases-302474775.html

SOURCE PR Newswire